Neuropace Stock Technical Analysis
| NPCE Stock | USD 15.74 0.61 4.03% |
As of the 2nd of February, Neuropace secures the Downside Deviation of 2.6, mean deviation of 3.03, and Risk Adjusted Performance of 0.095. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Neuropace, as well as the relationship between them. Please verify Neuropace value at risk, as well as the relationship between the semi variance and kurtosis to decide if Neuropace is priced some-what accurately, providing market reflects its recent price of 15.74 per share. Given that Neuropace has jensen alpha of 0.5797, we recommend you to check Neuropace's last-minute market performance to make sure the company can sustain itself at a future point.
Neuropace Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Neuropace, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to NeuropaceNeuropace | Build AI portfolio with Neuropace Stock |
Neuropace Analyst Consensus
| Target Price | Consensus | # of Analysts | |
| 19.38 | Strong Buy | 8 | Odds |
Most Neuropace analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Neuropace stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Neuropace, talking to its executives and customers, or listening to Neuropace conference calls.
Will Health Care Equipment & Supplies sector continue expanding? Could Neuropace diversify its offerings? Factors like these will boost the valuation of Neuropace. Anticipated expansion of Neuropace directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Neuropace data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.75) | Revenue Per Share | Quarterly Revenue Growth 0.299 | Return On Assets | Return On Equity |
Understanding Neuropace requires distinguishing between market price and book value, where the latter reflects Neuropace's accounting equity. The concept of intrinsic value—what Neuropace's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Neuropace's price substantially above or below its fundamental value.
It's important to distinguish between Neuropace's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Neuropace should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Neuropace's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Neuropace 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Neuropace's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Neuropace.
| 11/04/2025 |
| 02/02/2026 |
If you would invest 0.00 in Neuropace on November 4, 2025 and sell it all today you would earn a total of 0.00 from holding Neuropace or generate 0.0% return on investment in Neuropace over 90 days. Neuropace is related to or competes with Cerus, Rxsight, CVRx, 908 Devices, Brainsway, Senseonics Holdings, and Sight Sciences. NeuroPace, Inc. operates as a medical device company in the United States More
Neuropace Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Neuropace's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Neuropace upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.6 | |||
| Information Ratio | 0.1114 | |||
| Maximum Drawdown | 43.2 | |||
| Value At Risk | (4.61) | |||
| Potential Upside | 6.3 |
Neuropace Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neuropace's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Neuropace's standard deviation. In reality, there are many statistical measures that can use Neuropace historical prices to predict the future Neuropace's volatility.| Risk Adjusted Performance | 0.095 | |||
| Jensen Alpha | 0.5797 | |||
| Total Risk Alpha | 0.3927 | |||
| Sortino Ratio | 0.243 | |||
| Treynor Ratio | 0.2676 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Neuropace's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Neuropace February 2, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.095 | |||
| Market Risk Adjusted Performance | 0.2776 | |||
| Mean Deviation | 3.03 | |||
| Semi Deviation | 2.15 | |||
| Downside Deviation | 2.6 | |||
| Coefficient Of Variation | 838.12 | |||
| Standard Deviation | 5.67 | |||
| Variance | 32.17 | |||
| Information Ratio | 0.1114 | |||
| Jensen Alpha | 0.5797 | |||
| Total Risk Alpha | 0.3927 | |||
| Sortino Ratio | 0.243 | |||
| Treynor Ratio | 0.2676 | |||
| Maximum Drawdown | 43.2 | |||
| Value At Risk | (4.61) | |||
| Potential Upside | 6.3 | |||
| Downside Variance | 6.76 | |||
| Semi Variance | 4.64 | |||
| Expected Short fall | (3.92) | |||
| Skewness | 4.69 | |||
| Kurtosis | 29.4 |
Neuropace Backtested Returns
Neuropace appears to be somewhat reliable, given 3 months investment horizon. Neuropace has Sharpe Ratio of 0.16, which conveys that the firm had a 0.16 % return per unit of risk over the last 3 months. By analyzing Neuropace's technical indicators, you can evaluate if the expected return of 0.92% is justified by implied risk. Please exercise Neuropace's Risk Adjusted Performance of 0.095, downside deviation of 2.6, and Mean Deviation of 3.03 to check out if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Neuropace holds a performance score of 12. The company secures a Beta (Market Risk) of 2.49, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Neuropace will likely underperform. Please check Neuropace's kurtosis, market facilitation index, and the relationship between the semi variance and rate of daily change , to make a quick decision on whether Neuropace's current price movements will revert.
Auto-correlation | 0.12 |
Insignificant predictability
Neuropace has insignificant predictability. Overlapping area represents the amount of predictability between Neuropace time series from 4th of November 2025 to 19th of December 2025 and 19th of December 2025 to 2nd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Neuropace price movement. The serial correlation of 0.12 indicates that less than 12.0% of current Neuropace price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.12 | |
| Spearman Rank Test | -0.22 | |
| Residual Average | 0.0 | |
| Price Variance | 0.37 |
Neuropace technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Neuropace Technical Analysis
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of Neuropace volatility. High ATR values indicate high volatility, and low values indicate low volatility.
About Neuropace Technical Analysis
The technical analysis module can be used to analyzes prices, returns, volume, basic money flow, and other market information and help investors to determine the real value of Neuropace on a daily or weekly bases. We use both bottom-up as well as top-down valuation methodologies to arrive at the intrinsic value of Neuropace based on its technical analysis. In general, a bottom-up approach, as applied to this company, focuses on Neuropace price pattern first instead of the macroeconomic environment surrounding Neuropace. By analyzing Neuropace's financials, daily price indicators, and related drivers such as dividends, momentum ratios, and various types of growth rates, we attempt to find the most accurate representation of Neuropace's intrinsic value. As compared to a bottom-up approach, our top-down model examines the macroeconomic factors that affect the industry/economy before zooming in to Neuropace specific price patterns or momentum indicators. Please read more on our technical analysis page.
| 2023 | 2024 | 2025 | 2026 (projected) | Payables Turnover | 7.42 | 7.05 | 8.11 | 9.56 | Days Of Inventory On Hand | 236.61 | 234.57 | 269.76 | 273.68 |
Neuropace February 2, 2026 Technical Indicators
Most technical analysis of Neuropace help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Neuropace from various momentum indicators to cycle indicators. When you analyze Neuropace charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.095 | |||
| Market Risk Adjusted Performance | 0.2776 | |||
| Mean Deviation | 3.03 | |||
| Semi Deviation | 2.15 | |||
| Downside Deviation | 2.6 | |||
| Coefficient Of Variation | 838.12 | |||
| Standard Deviation | 5.67 | |||
| Variance | 32.17 | |||
| Information Ratio | 0.1114 | |||
| Jensen Alpha | 0.5797 | |||
| Total Risk Alpha | 0.3927 | |||
| Sortino Ratio | 0.243 | |||
| Treynor Ratio | 0.2676 | |||
| Maximum Drawdown | 43.2 | |||
| Value At Risk | (4.61) | |||
| Potential Upside | 6.3 | |||
| Downside Variance | 6.76 | |||
| Semi Variance | 4.64 | |||
| Expected Short fall | (3.92) | |||
| Skewness | 4.69 | |||
| Kurtosis | 29.4 |
Neuropace February 2, 2026 Daily Trend Indicators
Traders often use several different daily volumes and price technical indicators to supplement a more traditional technical analysis when analyzing securities such as Neuropace stock. With literally thousands of different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 0.05 | ||
| Daily Balance Of Power | 0.71 | ||
| Rate Of Daily Change | 1.04 | ||
| Day Median Price | 15.31 | ||
| Day Typical Price | 15.45 | ||
| Price Action Indicator | 0.73 | ||
| Market Facilitation Index | 0.86 |
Complementary Tools for Neuropace Stock analysis
When running Neuropace's price analysis, check to measure Neuropace's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuropace is operating at the current time. Most of Neuropace's value examination focuses on studying past and present price action to predict the probability of Neuropace's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuropace's price. Additionally, you may evaluate how the addition of Neuropace to your portfolios can decrease your overall portfolio volatility.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |